3rd Quarter - Report

HOSPIRA, INC. for HOSPIRA INC

Firm
Client
Income
—
Expenses
$280,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Issues relating to drug shortages; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94).

LobbyistCovered position, as disclosed
JULIANA REED —
WENDY SUSSMAN —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; White House Office; SENATE; Food & Drug Administration (FDA)

Health Issues HCR

Implementation of the Biologics Price Competition and Innovation Act (BPCIA) relating to biosimilar naming and reimbursement; issues related to drug approvals at the FDA including biosimilars.

LobbyistCovered position, as disclosed
JULIANA REED —
WENDY SUSSMAN —

Contacted: White House Office; HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.